Abstract 1857 GPR30/GPER Knockdown by siRNA and its effects on various Triple-Negative Breast Cancer Cell Lines

Triple negative breast cancer (TNBC) is a heterogeneous disease that makes up 15% of all breast cancer cases. The prognosis is poor for these patients since they are defined by the lack of estrogen, progesterone, and human epidermal growth factor receptors, which are receptors that are targeted as treatment for other breast cancers. To develop effective treatment methods for TNBC, additional targets need to be defined so that drugs can be developed to those targets. G-protein channel receptors (GPCR) are the majority of membrane receptors in eukaryotic cells and correspond with 30% of all identified drug targets.